* All trademarks are property of their respective owners.
Beckman Coulter and the stylized logo are registered trademarks of Beckman Coulter, Inc.
DMET Genotyping Service
Using the Affymetrix DMET Premier Plus Pack, Beckman Coulter Genomics provides a comprehensive assessment of metabolic and transporter genes, allowing you to use patient genotypes to predict drug response and metabolic potential.
Developed and validated as a collaboration between Beckman Coulter Genomics, Affymetrix, and Eli Lilly, the Affymetrix DMET Premier Plus Pac assays 1,936 markers in 225 genes includes all FDA validated biomarkers.
- Phase I Drug Metabolizing Enzymes (e.g. CYPs, ADHs, EPHs, ...)
- Phase II Drug Metabolizing Enzymes (e.g. NATs, UGTs, SULTs, GSTs, ...)
- Drug transport proteins (e.g. ABC transporters, drug uptake transporters, ...)
- Receptors (e.g. ADRB2, CAR, hPXR, ...)
- Includes rare markers with low minor allele frequency (MAF)
- Other genes of interest.
Core markers analytically validated against 96 sequence validated samples
CYP450s
| Gene | # of Markers |
|---|---|
| CYP1A2 | 6 |
| CYP2A6 | 7 |
| CYP2B6 | 10 |
| CYP2C19 | 12 |
| CYP2C8 | 3 |
| CYP2C9 | 10 |
| CYP2D6 | 23 |
| CYP2J2 | 5 |
| CYP3A4 | 2 |
| CYP3A5 | 8 |
Non-CYP Enzymes
| Gene | # of Markers |
|---|---|
| CDA | 2 |
| DPYD | 7 |
| FMO3 | 2 |
| GSTP1 | 1 |
| NAT1 | 12 |
| NAT2 | 6 |
| TPMT | 5 |
| UGT1A1 | 10 |
Transporters
| Gene | # of Markers |
|---|---|
| ABCB1 | 6 |
| ABCC2 | 6 |
| SLC15A2 | 4 |
| SLC22A1 | 4 |
| SLC22A2 | 3 |
| SLC01B1 | 9 |
Targets
| Gene | # of Markers |
|---|---|
| VKORC1 | 9 |
DMET was the first product available with comprehensive coverage of ADME drug metabolism biomarkers, including common and rare variations, insertions, deletions, copy number polymorphisms, triallelic SNPs and pseudogenes.
Benefits
- Co-Developer of DMET
- First DMET Commercial Provider
- Experience processing thousands of DMET arrays
- Regulatory-compliant service
- Automated star allele translation
- Rapid turnaround time of 5-7 days
